MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 119-129

  Shi, Lei ^a   Zhang, Shuguang ^a   Feng, Kun ^a   Wu, Furong ^a   Wan, Yi ^b   Wang, Zhimin ^b   Zhang, Junxia ^c   Wang, Yinyi ^c   Yan, Wei ^c   Fu, Zhen ^c   You, Yongping ^c  

^a JIANGSU UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bax; Bcl 2; MicroRNA; Peptide nucleic acids; Temozolomide

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; MICRORNA; MICRORNA 125B 2; MICRORNA 125B 2 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PEPTIDE NUCLEIC ACID; PROTEIN BAX; PROTEIN BCL 2; SMALL UNTRANSLATED RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR RESISTANCE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CYTOCHROMES C; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MICRORNAS; MITOCHONDRIA; NEOPLASTIC STEM CELLS; TUMOR CELLS, CULTURED;

EID: 84455194000     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1179     Document Type: Article

References (44)

1. Yung WK, Kyritsis AP, Gleason MJ and Levin VA: Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 2: 1931-1935, 1996. (Pubitemid 27006624)
2. Agarwala SS and Kirkwood JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5: 144-151, 2000.
3. Athanassiou H, Synodinou M, Maragoudakis E, et al.: Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23: 2372-2377, 2005. (Pubitemid 46218731)
4. Vescovi AL, Galli R and Reynolds BA: Brain tumour stem cells. Nat Rev Cancer 6: 425-436, 2006.
5. Singh SK, Hawkins C, Clarke ID, et al.: Molecular hydrogen beyond the optical edge of an isolated spiral galaxy. Nature 432: 396-401, 2004.
6. Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW and Ruohola-Baker H: Stem cell division is regulated by the microRNA pathway. Nature 435: 974-978, 2005.
7. Lee YS, Kim HK, Chung S, Kim KS and Dutta A: Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 280: 16635-16641, 2005.
8. Winkler JA, Hendricks WP, Johnson D, Xia J and Scheck AC: Global microRNA expression analysis in human malignant glioma cells reveals novel miRNA-mediated therapy-resistance mechanisms. AACR Meeting Abst, 1398, 2005.
9. Oh SY, Ju Y, Kim S and Park H: PNA-based antisense oligonucleotides for microrna s inhibition in the absence of a transfection reagent. Oligonucleotides 20: 225-230, 2010.
10. Manero F, Gautier F, Gallenne T, Cauquil N, Grée D and Cartron P: The small organic compound ha14-1 prevents bcl-2 interaction with bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66: 2757-2764, 2006.
11. Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M and Weller M: Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by bcl-2 and transforming growth factor-2. J Neurosci 21: 3360-3368, 2001. (Pubitemid 32422801)
12. Cartron P, Oliver L, Martin S, et al.: The expression of a new variant of the pro-apoptotic molecule Bax, Bax, is correlated with an increased survival of glioblastoma multiforme patients. Hum Mol Genet 11: 675-687, 2002. (Pubitemid 34285139)
13. Shinoura N, Yoshida Y, Nishimura M, et al.: Expression level of bcl-2 determines anti- or proapoptotic function. Cancer Res 59: 4119-4128, 1999. (Pubitemid 29393587)
14. Salakou S, Kardamakis D, Tsamandas AC, et al.: Increased Bax/ Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo 21: 123-132, 2007. (Pubitemid 46359209)
15. Shi L, Chen J, Yang J, et al.: MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352: 255-264, 2010.
16. Darling JL: The in vitro biology of human brain tumors. In: Neurooncology: Primary Malignant Brain Tumors. Thomas DGT (ed.) Johns Hopkins University Press, Baltimore, MD, pp1-25, 1990.
17. Chen C, Ridzon DA, Broomer AJ, et al.: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179, 2005.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 [-Delta Delta C(T)] method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
19. Ito H, Aoki H, Kühnel F, et al.: Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 98: 625-636, 2006. (Pubitemid 43904846)
20. Shi L, Zhang J, Pan T, Zhou J, et al.: MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res 1312: 120-126, 2010.
21. Ostermann S, Csajka C, Buclin T, et al.: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10: 3728-3736, 2004. (Pubitemid 38697606)
22. Oh SY, Ju Y and Park H: A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides. Mol Cells 28: 341-345, 2009.
23. Fu J, Liu ZG, Liu XM, et al.: Glioblastoma stem cells resistant to temozolomide-induced autophagy. Chin Med J 122: 1255-1259, 2009.
24. Narayan P, Mentzer RM Jr and Lasley RD: Annexin V staining during reperfusion detects cardiomyocytes with unique properties. Am J Physiol Heart Circ Physiol 281: H1931-H1937, 2001.
25. Xia HF, He TZ, Liu CM, et al.: MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem 23: 347-358, 2009.
26. Das A, Banik NL, Patel SJ and Ray SK: Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol Cancer 3: 36-45, 2009.
27. Bojes HK, Suresh PK, Mills EM, Spitz DR, Sim JE and Kehrer JP: Bcl-2 and Bcl-xL in peroxide-resistant A549 and U87MG cells. Toxol Sci 42: 109-116, 1998. (Pubitemid 28211139)
28. Terrano DT, Upreti M and Chambers TC: Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 30: 640-656, 2010.
29. Weller M, Schmidt C, Roth W and Dichgans J: Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 48: 1704-1709, 1997.
30. Katiyar SK, Roy AM and Baliga MS: Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther 4: 207-216, 2005. (Pubitemid 40340200)
31. Jarskog LF, Selinger ES, Lieberman JA and Gilmore JH: Apoptotic proteins in the temporal cortex in schizophrenia: high bax/bcl-2 ratio without caspase-3 activation. Am J Psychiatry 161: 109-115, 2004. (Pubitemid 38419315)
32. Hirose Y, Berger MS and Pieper RO: p53 effects both the duration of G2/M arrest and the fate of Temozolomide-treated human glioblastoma cells. Cancer Res 61: 1957-1963, 2001. (Pubitemid 32692013)
33. Kim JT, Kim JS, Ko KW, et al.: Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16: 33-39, 2006.
34. Fu J, Shao CJ, Chen FR, Ng HK and Chen ZP: Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neurooncology 12: 328-340, 2010.
35. Prokopenko O and Mirochnitchenko O: Ischemia-reperfusioninducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter. Am J Physiol Cell Physiol 296: C1086-C1097, 2009.
36. Mendes ND, Freitas AT and Sagot MF: Current tools for the identification of miRNA genes and their targets. Nucleic Acids Res 37: 2419-2433, 2009.
37. Reed JC: Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7: 541-546, 1995.
38. Ryan KM, Phillips AC and Vousden KH: Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-337, 2001. (Pubitemid 32429498)
39. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614-620, 1997.
40. Lee L, Irani K and Finkel T: Bcl-2 regulates non-apoptotic signal transduction: inhibition of c-Jun N-terminal kinase (JNK) activation by IL-1 beta and hydrogen peroxide. Mol Genet Metab 64: 19-24, 1998. (Pubitemid 28453314)
41. Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K and Gallo JM: Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomideacquired resistance. Biochem Pharmacol 63: 1219-1228, 2002. (Pubitemid 34311991)
42. Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ and Fritz LC: Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem 272: 30299-30305, 1997. (Pubitemid 27512235)
43. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997. (Pubitemid 27097313)
44. Zhivotovsky B, Orrenius S, Brustugun OT and Doskeland SO: Injected cytochrome c induces apoptosis. Nature 391: 449-450, 1998.